Tango Therapeutics, INC 10-Q quarterly reports

Tango Therapeutics announced promising efficacy data for its vopimetostat combination therapy in pancreatic cancer, alongside significant increases in R&D spending and continued net losses, highlighting ongoing capital requirements.

Tango Therapeutics reports Q1 2026 results, detailing ongoing clinical trials, financial position, and strategic pipeline advancements.

Tango Therapeutics announced its Q3 2025 financial results, highlighting positive clinical data for vopimetostat and a strong cash runway into 2028 following a recent $212 million capital raise.

Tango Therapeutics reported a wider net loss in Q2 2025, driven by decreased collaboration revenue and increased R&D for key oncology programs, while extending its cash runway into Q1 2027.

Tango Therapeutics reports a net loss of $39.9 million for Q1 2025 and anticipates funding operations into Q1 2027 with existing cash reserves.

Tango Therapeutics announced its third quarter 2024 financial results, highlighting progress in its clinical programs and providing updates on its pipeline.

Tango Therapeutics reports a net loss of $63.5 million for the first half of 2024, while advancing its clinical programs and highlighting upcoming data releases.

Tango Therapeutics reported a net loss of $37.9 million for the first quarter of 2024, while advancing its clinical programs and maintaining a strong cash position.